Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Renagel sevelamer: Marketed in the EU and U.S.; Phase III in Japan

UCLA School of Medicine researchers (Los Angeles, Calif.) published in The New England Journal of Medicine that young adults with ESRD undergoing dialysis

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE